Substipharm Pharmaceutical Import Profile — France (DGFT 2022–2026)

Name: Substipharm Pharmaceutical Import Records from India — 3 Products, $7.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Substipharm — Pharmaceutical Importer Profile (2026) | 3 Products, $7.3M Trade | TransData Nexus

Substipharm

Pharmaceutical Importer · France · Analgesics & Antipyretics Focus · $7.3M Total Trade · DGFT Verified

Substipharm is a pharmaceutical importer based in France with a total trade value of $7.3M across 3 products in 3 therapeutic categories. Based on 209 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Substipharm sources from 1 verified Indian supplier, with Medreich Limited accounting for 100.0% of imports.

Substipharm — Import Portfolio & Supplier Network

Substipharm import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Substipharm?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Medreich Limited	$24.2M	991	100.0%

Substipharm sources from 1 verified Indian supplier across 620 distinct formulations. The sourcing is highly concentrated — Medreich Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Substipharm Import?

Formulation	Value	Ships
Tramadol hydrochloride 37.5MG and	$619.7K	20
Tramadol paracetamol 37.5/325MG film	$414.7K	9
Ursodeoxycholic acid 500MG film coated	$400.0K	8
Ursodeoxycholic acid tablets 250MG	$350.0K	7
Urapidil 60MG capsules(urapidil biogaran60mg) 30s (92727 packs)	$350.0K	7
Tramadol paracetamol 37.5MG/325MG film coatedtab (tramadol+paracetamol mylan 375MG+325MG tablets) 2x10s(99792 packs)	$350.0K	7
Ursodeoxycholic acid biogaran 250MG	$242.1K	5
Tramadol hydrochloride 37.5MG and paracetamol 325MG TAB(tramadol/paracetamol bgr37.5MG/325MG tablets)2x10s(91437 packs)	$235.5K	7
Urapidil 60MG capsules (urapidil	$200.0K	4
Ursodeoxycholic acid tablets 250MG	$200.0K	4
Rupatadine 10MG tablets (rupaller 10MG	$185.1K	5
Ursodeoxycholic acid biogran 250MG	$158.9K	4
Rupatadine tablets 10MG (rupatadine	$154.0K	6
Urapidil 60MG capsules (urapidil	$150.0K	3
Urapidil 60MG capsules (urapidil viatrislp 60MG capsules) 30s (99741 packs)	$150.0K	3

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Tramadol	Analgesics & Antipyretics	$6.8M	190	1.8%	4
2	Nifedipine	Cardiovascular	$376.0K	14	1.2%	14
3	Bisacodyl	Gastrointestinal	$148.5K	5	1.7%	8

Substipharm imports 3 pharmaceutical products across 3 categories into France totaling $7.3M.

Substipharm — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Substipharm is a privately held French pharmaceutical group headquartered in Paris, France. Established in 1995, the company specializes in the development, registration, and commercialization of generic and specialty drugs, as well as vaccines. With a portfolio exceeding 90 different molecules, Substipharm operates in over 90 countries, including direct presence in Europe and Southeast Asia.

The company's operations are divided into two main divisions: Pharmaceuticals and Biologics. The Pharmaceuticals division focuses on branded specialties and generics, while the Biologics division is dedicated to vaccines, particularly the Japanese Encephalitis vaccine, IMOJEV®. Substipharm's business model combines in-house development of pharmaceutical dossiers with direct commercialization and strategic partnerships.

2Distribution Network

Substipharm's distribution network is extensive, with operations spanning over 90 countries worldwide. The company has established commercial affiliates in key markets, including the United Kingdom, Italy, and Switzerland. In the UK, Substipharm operates through its affiliate, Vygoris, which commenced sales of its product portfolio in 2016. The Italian affiliate, Substipharm Srl, was established in 2020 to further expand its European presence. Additionally, Substipharm has a subsidiary in Geneva, Switzerland, and a biologics division in Bangkok, Thailand, focusing on the distribution of IMOJEV® in Southeast Asia.

3Industry Role

In France's pharmaceutical supply chain, Substipharm functions as a pharmaceutical importer and distributor. The company imports finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, from various countries, including India. Substipharm's role encompasses both direct commercialization of its own product portfolio and the supply of products through licensing and distribution partnerships. This dual approach allows the company to serve a broad spectrum of the pharmaceutical market, from generics to specialty drugs and vaccines.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Substipharm

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Substipharm's sourcing strategy exhibits a high degree of concentration, with a significant reliance on a single supplier, MEDREICH LIMITED, accounting for 100% of its pharmaceutical imports from India. This exclusive partnership has resulted in 991 shipments, indicating a stable and long-term relationship. While such concentration can lead to favorable terms and streamlined logistics, it also poses risks related to supply chain disruptions, regulatory changes, or operational issues within the supplier. Diversifying the supplier base could mitigate these risks and enhance supply chain resilience.

2Supply Chain Resilience

The resilience of Substipharm's Indian supply chain is closely tied to its exclusive relationship with MEDREICH LIMITED. The absence of backup suppliers for Indian imports suggests potential vulnerabilities in the event of disruptions. The company's import portfolio comprises 620 unique formulations, indicating a diverse range of products. However, the heavy reliance on a single supplier for these formulations may limit flexibility and responsiveness to market changes. Ensuring that MEDREICH LIMITED adheres to international quality standards and maintains robust operational capabilities is crucial for sustaining supply chain stability.

Strategic Implications

Importing Pharmaceuticals into France — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for France

1Regulatory Authority & Framework

In France, the primary regulatory authority overseeing pharmaceutical imports is the French National Agency for Medicines and Health Products Safety (ANSM). The agency is responsible for ensuring that all medicinal products, including those imported from countries like India, meet stringent safety, efficacy, and quality standards. Key legislation governing pharmaceutical imports includes the French Public Health Code, which aligns with European Union directives and regulations. The marketing authorization pathway for Indian generics involves obtaining a Marketing Authorization (MA) from ANSM, which requires comprehensive documentation demonstrating bioequivalence to the reference product, compliance with Good Manufacturing Practice (GMP), and adherence to labeling and packaging requirements.

2Import Licensing & GMP

Import licensing in France necessitates that foreign manufacturers hold a valid GMP certificate recognized by ANSM. Certificates from the World Health Organization (WHO) or the Pharmaceutical Inspection Co-operation Scheme (PIC/S) are typically accepted. Indian exporters must ensure that their manufacturing facilities comply with these standards to facilitate market entry. Additionally, wholesalers like Substipharm must obtain authorization from ANSM to distribute pharmaceutical products within France. This authorization process includes demonstrating compliance with storage, handling, and distribution regulations to ensure product integrity and patient safety.

Substipharm — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Substipharm's focus on importing analgesics and antipyretics, particularly tramadol, aligns with the high demand for pain management medications in France. The inclusion of cardiovascular and gastrointestinal products indicates a strategic approach to address prevalent health conditions. The company's portfolio of over 90 molecules, including mature brands and generics, reflects a commitment to providing comprehensive therapeutic solutions. This diverse product strategy enables Substipharm to cater to a wide patient demographic and maintain a competitive edge in the market.

2Sourcing Profile

Substipharm's sourcing strategy emphasizes the importation of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, from India. This approach allows the company to leverage India's manufacturing capabilities and cost advantages while focusing on the commercialization and distribution aspects within France. The reliance on a single supplier, MEDREICH LIMITED, suggests a strategic choice to streamline operations and maintain consistency in product quality. However, exploring additional suppliers could enhance supply chain resilience and mitigate potential risks associated with supplier dependency.

3Market Positioning

Seller's Guide — How to Become a Supplier to Substipharm

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the French market by partnering with Substipharm. To capitalize on this opportunity, Indian exporters should focus on demonstrating product quality, compliance with regulatory standards, and the ability to meet market demands. Diversifying Substipharm's supplier base could lead to more competitive pricing and a broader product offering, benefiting both the company and its customers.

2Requirements & Qualifications

Indian exporters aiming to supply Substipharm and the French market must ensure compliance with ANSM's GMP standards, which are recognized by WHO and PIC/S. Obtaining a valid GMP certificate from these organizations is essential for import authorization. Additionally, products must meet French labeling requirements, including French language labeling and serialization mandates. Engaging with regulatory consultants familiar with French pharmaceutical regulations can facilitate the compliance process.

3How to Approach

Frequently Asked Questions — Substipharm

What products does Substipharm import from India?

Substipharm imports 3 pharmaceutical products across 3 categories. Top imports: Tramadol ($6.8M), Nifedipine ($376.0K), Bisacodyl ($148.5K).

Who supplies pharmaceuticals to Substipharm from India?

Substipharm sources from 1 verified Indian suppliers. The primary supplier is Medreich Limited (100.0% of imports, $24.2M).

What is Substipharm's total pharmaceutical import value?

Substipharm's total pharmaceutical import value from India is $7.3M, based on 209 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Substipharm focus on?

Substipharm imports across 3 categories. The largest: Analgesics & Antipyretics (92.8%), Cardiovascular (5.2%), Gastrointestinal (2.0%).

Get Full Substipharm Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.